Hisashi Haga

Closest collaborators

The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Atsushi Enomoto · 3 shared papers, 2022–2026 · strength 0.59
   • Paper Compressive stress inhibits proliferation in AsPC-1 pancreatic cancer cells and reduction of Myc protein. DOI 10.1371/journal.pone.0352769↗
   • Paper Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves … DOI 10.1038/s41388-022-02288-9↗
   • Paper Correction: Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenoty… DOI 10.1038/s41388-022-02336-4↗
2. Fuko Miyake · 1 shared paper, 2026 · strength 0.36
   • Paper Compressive stress inhibits proliferation in AsPC-1 pancreatic cancer cells and reduction of Myc protein. DOI 10.1371/journal.pone.0352769↗
3. Shoichiro Tange · 1 shared paper, 2026 · strength 0.36
   • Paper Compressive stress inhibits proliferation in AsPC-1 pancreatic cancer cells and reduction of Myc protein. DOI 10.1371/journal.pone.0352769↗
4. Tadashi Iida · 2 shared papers, 2022 · strength 0.24
   • Paper Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves … DOI 10.1038/s41388-022-02288-9↗
   • Paper Correction: Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenoty… DOI 10.1038/s41388-022-02336-4↗
5. Takuya Ishikawa · 2 shared papers, 2022 · strength 0.24
   • Paper Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves … DOI 10.1038/s41388-022-02288-9↗
   • Paper Correction: Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenoty… DOI 10.1038/s41388-022-02336-4↗
6. Shinji Mii · 2 shared papers, 2022 · strength 0.24
   • Paper Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves … DOI 10.1038/s41388-022-02288-9↗
   • Paper Correction: Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenoty… DOI 10.1038/s41388-022-02336-4↗
7. Hiroki Kawashima · 2 shared papers, 2022 · strength 0.24
   • Paper Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves … DOI 10.1038/s41388-022-02288-9↗
   • Paper Correction: Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenoty… DOI 10.1038/s41388-022-02336-4↗
8. Yasuyuki Mizutani · 2 shared papers, 2022 · strength 0.24
   • Paper Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves … DOI 10.1038/s41388-022-02288-9↗
   • Paper Correction: Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenoty… DOI 10.1038/s41388-022-02336-4↗
9. Eizaburo Ohno · 2 shared papers, 2022 · strength 0.24
   • Paper Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves … DOI 10.1038/s41388-022-02288-9↗
   • Paper Correction: Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenoty… DOI 10.1038/s41388-022-02336-4↗
10. Atsushi Masamune · 2 shared papers, 2022 · strength 0.24
    • Paper Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves … DOI 10.1038/s41388-022-02288-9↗
    • Paper Correction: Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenoty… DOI 10.1038/s41388-022-02336-4↗
11. Mitsuhiro Fujishiro · 2 shared papers, 2022 · strength 0.24
    • Paper Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves … DOI 10.1038/s41388-022-02288-9↗
    • Paper Correction: Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenoty… DOI 10.1038/s41388-022-02336-4↗
12. Yoshiki Hirooka · 2 shared papers, 2022 · strength 0.24
    • Paper Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves … DOI 10.1038/s41388-022-02288-9↗
    • Paper Correction: Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenoty… DOI 10.1038/s41388-022-02336-4↗
13. Kunio Kataoka · 1 shared paper, 2022 · strength 0.12
    • Paper Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves … DOI 10.1038/s41388-022-02288-9↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.